


Figure 4. Sparse pharmacokinetic analysis of trebananib during cycle 2



*p < 0.01 (compared with C2D1 pre-dose or C2D8 pre-dose for each dose level);

δ p < 0.01 (comparing C2D1 10 min plasma concentration between DL-1 and DL-2)